Pregabalin Ivax 25/50/75/150 25/50/75/150 mg Capsules
PDF Leaflet Revision Date: 14 April 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of neuropathic pain due to Herpes zoster infections and diabetes.
Dosage (summary)
Starting dose: 75 mg twice daily; may increase to 150 mg twice daily after 3-7 days.
Special Populations
- Renal impairment
- Elderly
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; excreted in breast milk.
Key Drug Interactions
- CNS depressants
- Opioids
- Anti-depressants
Contraindications
- Hypersensitivity to pregabalin or excipients
Common side effects
- Dizziness
- Somnolence
- Increased appetite
- Fatigue
Counselling Points
- Avoid driving until effects are known
- Gradual discontinuation recommended
- Monitor for signs of misuse or dependence
Serious warnings
- Hypersensitivity reactions
- Severe cutaneous adverse reactions
- Risk of respiratory depression
Important Disclaimer
The Pregabalin Ivax 25/50/75/150 25/50/75/150 mg Capsules professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
